451 related articles for article (PubMed ID: 17671176)
21. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET
J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084
[TBL] [Abstract][Full Text] [Related]
22. Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.
Izumi H; Inoue J; Yokoi S; Hosoda H; Shibata T; Sunamori M; Hirohashi S; Inazawa J; Imoto I
Hum Mol Genet; 2005 Apr; 14(8):997-1007. PubMed ID: 15746151
[TBL] [Abstract][Full Text] [Related]
23. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis.
Chang CC; Shih JY; Jeng YM; Su JL; Lin BZ; Chen ST; Chau YP; Yang PC; Kuo ML
J Natl Cancer Inst; 2004 Mar; 96(5):364-75. PubMed ID: 14996858
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic silencing of Aristaless-like homeobox-4, a potential tumor suppressor gene associated with lung cancer.
Liu WB; Han F; Du XH; Jiang X; Li YH; Liu Y; Chen HQ; Ao L; Cui ZH; Cao J; Liu JY
Int J Cancer; 2014 Mar; 134(6):1311-22. PubMed ID: 24037716
[TBL] [Abstract][Full Text] [Related]
25. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
26. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.
Kuo KT; Mao TL; Jones S; Veras E; Ayhan A; Wang TL; Glas R; Slamon D; Velculescu VE; Kuman RJ; Shih IeM
Am J Pathol; 2009 May; 174(5):1597-601. PubMed ID: 19349352
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells.
Izutsu N; Maesawa C; Shibazaki M; Oikawa H; Shoji T; Sugiyama T; Masuda T
Int J Oncol; 2008 Jun; 32(6):1227-35. PubMed ID: 18497984
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia upregulates ovarian cancer invasiveness via the binding of HIF-1α to a hypoxia-induced, methylation-free hypoxia response element of S100A4 gene.
Horiuchi A; Hayashi T; Kikuchi N; Hayashi A; Fuseya C; Shiozawa T; Konishi I
Int J Cancer; 2012 Oct; 131(8):1755-67. PubMed ID: 22287060
[TBL] [Abstract][Full Text] [Related]
29. Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival.
Barton CA; Gloss BS; Qu W; Statham AL; Hacker NF; Sutherland RL; Clark SJ; O'Brien PM
Br J Cancer; 2010 Jan; 102(1):87-96. PubMed ID: 19935792
[TBL] [Abstract][Full Text] [Related]
30. Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical Wnt signaling pathway.
Wang J; Cai J; Han F; Yang C; Tong Q; Cao T; Wu L; Wang Z
Int J Gynecol Cancer; 2011 Aug; 21(6):981-7. PubMed ID: 21738044
[TBL] [Abstract][Full Text] [Related]
31. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.
Moran-Jones K; Gloss BS; Murali R; Chang DK; Colvin EK; Jones MD; Yuen S; Howell VM; Brown LM; Wong CW; Spong SM; Scarlett CJ; Hacker NF; Ghosh S; Mok SC; Birrer MJ; Samimi G
Oncotarget; 2015 Dec; 6(42):44551-62. PubMed ID: 26575166
[TBL] [Abstract][Full Text] [Related]
32. Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers.
Gloss BS; Patterson KI; Barton CA; Gonzalez M; Scurry JP; Hacker NF; Sutherland RL; O'Brien PM; Clark SJ
Cancer Lett; 2012 May; 318(1):76-85. PubMed ID: 22155104
[TBL] [Abstract][Full Text] [Related]
33. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
34. [Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors].
Ma L; Zhang JH; Liu FR; Zhang X
Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):657-9. PubMed ID: 16438885
[TBL] [Abstract][Full Text] [Related]
35. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
[TBL] [Abstract][Full Text] [Related]
36. Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers.
Dong Y; Kaushal A; Brattsand M; Nicklin J; Clements JA
Clin Cancer Res; 2003 May; 9(5):1710-20. PubMed ID: 12738725
[TBL] [Abstract][Full Text] [Related]
37. P73 gene expression in ovarian cancer tissues and cell lines.
Chen CL; Ip SM; Cheng D; Wong LC; Ngan HY
Clin Cancer Res; 2000 Oct; 6(10):3910-5. PubMed ID: 11051237
[TBL] [Abstract][Full Text] [Related]
38. RECQL1 DNA repair helicase: a potential therapeutic target and a proliferative marker against ovarian cancer.
Sanada S; Futami K; Terada A; Yonemoto K; Ogasawara S; Akiba J; Yasumoto M; Sumi A; Ushijima K; Kamura T; Furuichi Y; Yano H
PLoS One; 2013; 8(8):e72820. PubMed ID: 23951333
[TBL] [Abstract][Full Text] [Related]
39. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells.
Gery S; Xie D; Yin D; Gabra H; Miller C; Wang H; Scott D; Yi WS; Popoviciu ML; Said JW; Koeffler HP
Clin Cancer Res; 2005 Oct; 11(20):7243-54. PubMed ID: 16243794
[TBL] [Abstract][Full Text] [Related]
40. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors.
Milde-Langosch K; Ocon E; Becker G; Löning T
Int J Cancer; 1998 Feb; 79(1):61-5. PubMed ID: 9495360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
